

1/24

Intranasal application of Transfersulin
IDDM test person, -0.8 IU/kg




Fig. 1

2/24

Intranasal application of Transfersulin
on a normoglycaemic test person, ~ 0.15 IU/kg (2x)




Fig. 2

3/24

Intranasal application of Transfersulin
on a normoglycaemic test person, ~ 0.15 IU/kg (2x)




Fig. 3a

4/24

Intranasal application of Transfersulin
in IDDM test person, -0.4 IU/kg




Fig. 3b

5/24

Effects of nasally administered
cytokines on specific immune response,
1st boost + 7 d




Fig. 4

6/24




Fig. 5

7/24





Fig. 6

8/24

Intranasal administration: Tetanus toxoid (TT, impure)




Reciprocal antiserum dilution x 10²

Fig. 7a

9/24

Intranasal immunisation: Tetanus toxoid (TT impure)



Reciprocal antiserum dilution x 10²

- SPC:NaCh (4.5:1)
- Mixed micelles (SNa 1:1)
- ▲— SPC:Cholesterol (1:1)

Antigen dose in all the groups : 40 µg per mouse

Fig. 7b

Intranasal immunisation: Tetanus toxoid (TT, impure) Effect of carrier size and deformability




Fig. 7c

11/24

Intranasal Immunization: Tetanus toxoid, (TT, purified)
dose effect




Fig. 8a

Intranasal immunisation: Tetanus toxoid (TT, purified), Effect of antigen dose




Fig. 8b

Intranasal Immunization: Tetanus toxoid (TT, purified), dose effect




Fig. 8c

145067/60890371

Noninvasive immunisation: Tetanus toxoid (TT, purified) effect of application route




Fig. 9a





Fig. 9b

Antigen-specific Isotyping: Intranasal / Subcutaneous

40 µg Tetanus Toxoid (TT), ultrafiltered



Antiserum dilution Fig. 9c

Intranasal immunisation: Tetanus toxoid (TT)

dose and route of administration effect




Fig. 10a

18/24

Intranasal immunisation: Tetanus toxoid (TT, purified) dose effect




Fig. 10b

Intranasal immunisation: Tetanus toxoid (TT, impure)
effect of immunomodulators





Fig. 11a

Intranasal immunisation: Tetanus toxoid (TT, impure, 40 µg), effect of immunomodulators,



- ◇ i.n. TT in Tfs
 - i.n. TT in Tfs + IFN-γ
 - ▲ i.n. TT in Tfs + GM-CSF + IL-4
 - ▼ i.n. TT in Tfs + IL-4
 - ◆ i.n. TT in Tfs + IL-12
 - s.c. TT in Tfs
- SPC:Tw-80 3.5:1

Fig. 11b

Intranasal immunisation: Tetanus toxoid (TT, purified)
effect of immunopotentiators





Fig. 12

22/24
Potentiation of nasal immune response to tetanus
toxoid (TT) by bacterial adjuvant, cholera toxin (CT)



TfsT: SPC:Tw80(1:1)

TfsC: SPC:NaCholate(3.75:1)

CT dose: 2µg per dose

Time after challenge (hours)




Fig. 13

Adjuvant effect: of Heat Labile Toxin (LT) from E.coli




Fig. 14

Bi-Valent Vaccines: Anti-Tetanus and -Cholera response to the antigens administration in Transfersomes in the nose




Fig. 15